{"_id": "65013a5cfddc0bb1312fb038", "and": [{"age": {"$gte": 18, "$lte": 79}}, {"diagnosis": "locoregionally recurrent or second primary HNSCC in a previously radiated field"}, {"surgery": {"$lt": 56}}, {"$and": [{"positive margins and/or extra nodal extension (ENE)": true}, {"$or": [{"positive margins defined as malignancy at or within 1 mm of the margin": true}, {"high grade dysplasia (i.e. carcinoma in situ) at the margin": true}]}, {"ENE may be either gross or microscopic": true}]}, {"PD-L1 Combined Positive Score (CPS)": {"$gte": 1}}, {"prior radiation to the area of recurrent or second primary tumor": true}, {"completed prior radiation a minimum of 6 months prior to randomization": true}, {"no evidence of distant disease based on baseline imaging done within 28 days prior to randomization": true}, {"no anti-PD-1/PD-L1 therapy for recurrent disease": true}, {"Eastern Cooperative Oncology Group (ECOG) performance status": {"$in": [0, 1]}}, {"able to understand and willingness to sign a written informed consent document": true}, {"$or": [{"not pregnant": true}, {"not breastfeeding": true}]}, {"$and": [{"not expecting to conceive or father children": true}, {"using accepted and effective method(s) of contraception or abstaining from sexual intercourse while on study treatment, and continue for 120 days after the last dose of study treatment": true}]}, {"ANC": {"$gte": 1500}}, {"platelets": {"$gte": 100000}}, {"total bilirubin": {"$lte": 1.5}}, {"Aspartate aminotransferase (AST)/alanine aminotransferase (ALT)": {"$lte": 3.0}}, {"Creatinine clearance": {"$gt": 30}}, {"no current active infection that requires systemic treatment at time of randomization": true}, {"no history of non-infectious pneumonitis requiring steroids within 3 years prior to randomization": true}, {"no history of solid organ transplant or stem cell transplant": true}, {"$not": {"$and": [{"not on immunosuppressive medication within 7 days prior to randomization": true}, {"$or": [{"intranasal, inhaled, topical steroids, or local steroid injection": true}, {"systemic corticosteroids at physiologic doses": {"$lte": 10}}, {"steroids as premedication for hypersensitivity reactions": true}]}]}}, {"clinical risk assessment of cardiac function using the New York Heart Association Functional classification": true}, {"no live vaccine within 30 days prior to the first dose of study drug": true}, {"no severe hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipients": true}, {"$not": {"$and": [{"no active autoimmune disease that has required systemic treatment in past 2 years": true}, {"replacement therapy is not considered a form of systemic treatment": true}]}}, {"no known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study": true}, {"$or": [{"$and": [{"HIV-infected patients on effective anti-retroviral therapy": true}, {"undetectable viral load within 6 months": true}]}, {"$not": {"$or": [{"known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive)": true}, {"known active hepatitis C virus (defined as HCV ribonucleic acid [RNA] [qualitative] is detected) infection": true}]}}]}], "nctId": "NCT04671667", "title": "A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features"}